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ABSTRACT
Neisseria gonorrhoeae is the most common sexually
transmitted disease-causing bacterium world-
wide. An in-house PCR assay targeting the
carbamoyl-phosphate synthase subunit A (carA)
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gene was developed for the specific detection of
N. gonorrhoeae in clinical specimens. Samples
from 605 patients were cultured on selective
medium and assayed by PCR in a double-blind
fashion. Of 605 urethral ⁄ cervical samples ana-
lysed, 13 were PCR-positive, of which 11 were
culture-positive. The PCR showed a sensitivity
and specificity of 100% and 99.7% with these
samples. PCR targeting the carA gene appears
to be a reliable method for the detection of
N. gonorrhoeae in clinical specimens.
Keywords carA gene, diagnosis, Neisseria gonorrhoeae,
PCR, sexually transmitted disease, swab samples
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Approximately 62 million new infections with
Neisseria gonorrhoeae occur annually worldwide.
N. gonorrhoeae infects the mucous membranes of
the urethra, endocervix, pharynx or rectum, and
causes gonorrhoea, a disease that may result in
substantial morbidity [1]. Gonorrhoea also causes
disseminated disease [2], with complications that
may result in infertility [3], ectopic pregnancy,
chronic pelvic pain [4] or maternal transmission
of gonorrhoea [5], and also increases susceptibil-
ity to human immunodeficiency virus (HIV) [6].
Conventional diagnosis of gonorrhoea requires
culture on selective media or an observation of
Gram-negative intracellular diplococci in smears
of urethral or endocervical swabs. The sensitivity
of culture for acute gonorrhoea is high, but
decreases to 50% in chronic infections [7]. Poor
sampling techniques and improper specimen
storage and transport can decrease culture sensi-
tivity further [8–10].
Although commercially available assays based
on nucleic acid amplification have greater sensi-
tivity than conventional assays for detecting
N. gonorrhoeae [11–13], specificity remains an
issue, since intra- and inter-species genetic recom-
bination occurs frequently among members of the
genus Neisseria. Cross-reactivity is common with
most target sequences, including the 16S rRNA
gene [7,14,15], and false-positive results with
Neisseria meningitidis and Neisseria lactamica have
been reported using cppB gene sequences [16,17].
The aim of the present study was to improve
the specificity of molecular detection of N. gonor-
rhoeae by the use of a reliable PCR assay for the
carbamoyl-phosphate synthase subunit A (carA)
gene. Primers NgCPS1, 5¢-CGGCATCGTAGC-
GCGCACAG, and NgCPS4, 5¢-CGGCTGCTGTC-
GTCGGCGGAAT, were designed to amplify a
412-bp fragment, based on unique regions of the
carA gene of N. gonorrhoeae strains F1090 and
MS11 (Gene Bank Accession Numbers AF029362
and AF029363).
Clinical specimens were collected from 605
patients with different degrees of risk for sexually
transmitted disease (STD) who attended the Dos
De Mayo and Arzobispo Loayza hospitals, Lima,
Peru. The high-risk STD group from Dos De
Mayo hospital (51 males and 38 females) included
29 (32.6%) patients with HIV infection, 11 (12.4%)
with syphilis, and six (7%) with herpes simplex
virus infection. The moderate-risk STD group
from Arzobispo Loayza hospital (156 males and
183 females) included 18 (5.3%) patients with
syphilis and one HIV-positive patient. The low-
risk STD group from Dos de Mayo Hospital (80
males and 97 females) included four (2.3%)
patients with syphilis.
In total, 1815 duplicate swabs (calcium alginate
swabs; Fisher-Scientific, Pittsburgh, PA, USA)
were obtained from the posterior pharynx, rectum
and urethra (or cervix). A 10-mL sample of urine
was also collected from each patient. The first
swab was inoculated, at the bedside, on to a
selective medium (chocolate agar plus Isovitalex
supplements) and used to make a smear for
Gram’s-staining [9,18]. The second swab was
placed in a tube containing 500 lL of 10 mM
Tris-HCl, pH 8.0, transported under refrigerated
conditions to the molecular biology laboratory,
and processed as described previously [16,19].
Urine samples were centrifuged at 3000 g for
5 min and the sediment was washed twice with
10 mM Tris-HCl, pH 8.0. The washed sediment
was resuspended in 100 lL of 10 mM Tris-HCl,
pH 8.0, and then processed as described previ-
ously [19].
Identification of N. gonorrhoeae was performed
by Gram’s stain, oxidase and catalase tests,
growth on chocolate agar and culture on trypti-
case-soy agar. Further identification was per-
formed with the Syva MicroTrak Neisseria
gonorrhoeae culture confirmation kit (Behring
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Diagnostic, San Jose, CA, USA) and carbohydrate
utilisation reactions.
PCR was performed in 25-lL volumes contain-
ing 1 · PCR buffer (Perkin Elmer-Cetus, La Jolla,
CA, USA), 2.0 mM MgCl2, 0.25 mM each dNTP,
0.6 lM each primer and 1.25 U of Taq DNA
polymerase (Invitrogen, Carlsbad, CA, USA) in a
PTC-100 cycler (MJ Research, Waltham, MA,
USA), with denaturation at 94C for 2 min,
followed by 30 cycles of 94C for 30 s, 62C for
45 s and 72C for 45 s, and a final extension at
72C for 5 min. Amplification of N. gonorrhoeae
yielded a single 412-bp fragment with an analyt-
ical sensitivity equivalent to 50 fg of N. gonor-
rhoeae DNA. Specificity was confirmed by
restriction enzyme analysis; only N. gonorrhoeae
strains generated fragments of 275 bp and 147 bp
following digestion with AvaI.
Of the 605 patients tested, 11 (2.8%) had a
definitive diagnosis of gonorrhoea, with positive
results by both culture and PCR. The distribution
of PCR and culture results according to risk group
and gender are shown in Table 1. Two (28.6%) of
seven patients with a definitive diagnosis of
gonorrhoea in the high-risk STD group were
HIV-positive; the remaining gonorrhoea-positive
patients were HIV-negative.
N. gonorrhoeae was isolated by culture from ten
urethral swabs and one cervical swab. None of the
rectal or pharyngeal swabs were positive by
culture. Of the six presumptive patients (positive
by PCR only), three were male and three were
female. Two of the males were symptomatic: one
presented with only a positive rectal swab, while
the other presented with positive urethral, urine
and pharyngeal samples. The third male was
asymptomatic, and had a positive urethral swab
by PCR. The presumptive gonorrhoea-positive
females comprised two who were symptomatic
and one who was asymptomatic. Both of the
symptomatic patients had urine samples that
were positive by PCR; the asymptomatic female
only yielded a rectal swab that was positive by
PCR. Of the five (1.7%) patients with rectal swabs
positive by PCR, three also had PCR-positive
urethral samples (Table 2). Considering culture as
the reference standard, the sensitivity and specif-
icity of the PCR assay were 100% and 99.7%,
respectively, for cervical and urethral samples.
In conclusion, the PCR assay described in this
study detected N. gonorrhoeae in a variety of
clinical samples, and was highly specific and
more sensitive in comparison with culture. An
important characteristic of the carA gene used as
the DNA target is its lack of cross-reactivity with
most other Neisseria and non-Neisseria spp. Urine
screening is important because it is a non-invasive
method that is ideally suited for screening asymp-
tomatic high-risk individuals. However, in this
study, the sensitivity of PCR with urine speci-
mens was low in comparison with data published
previously [20]. Nevertheless, this study demon-
strated the value of a PCR assay for the specific
Table 1. Comparison of culture and
PCR for detection of Neisseria gonor-
rhoeae according to risk of sexually
transmitted disease (STD), gender
and total number of samples Risk of STD
Males Females
Total
Culturea PCRb Culture PCR
Positive Negative Positive Negative Positive Negative Positive Negative
High
Patients 7 44 9 42 0 38 0 38 89
Samples 7 146 17 187 0 114 0 152 623
Moderate
Patients 2 154 2 154 1 182 2 181 339
Samples 2 466 4 620 1 548 2 730 2373
Low
Patients 1 79 3 77 0 97 0 97 177
Samples 1 239 5 315 0 291 0 388 1239
aThe number of samples includes one cervical or urethral, one rectal and one pharyngeal sample per patient.
bThe number of samples includes one cervical or urethral, one rectal, one pharyngeal and one urine sample per
patient.
Table 2. Specimens positive for Neisseria gonorrhoeae by
culture and ⁄ or PCR by type of sample in 605 patients
Urethral ⁄ cervical
swabs
Rectal swabsa
PCR
Pharyngeal swabsa
PCR
Urineb
PCRCulture PCR
8 8 0 0 5
3 3 3 0 2
0 0 2 0 1
0 1 0 1 1
0 1 0 0 0
11 ⁄ 605 13 ⁄ 605 5 ⁄ 605 1 ⁄ 605 9 ⁄ 605
aIsolation of N. gonorrhoeae was not possible from specimens collected from the
rectum or the pharynx.
bUrine samples were tested only by PCR.
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detection of N. gonorrhoeae in a country with a low
prevalence, such as Peru. The negative results for
97% of the patients provided a high negative
predictive value of 100%, which is an important
parameter for a test to be used in settings with a
low prevalence.
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ABSTRACT
Neisseria meningitidis W-135 accounted for nine
(1.6%) of 562 cases of invasive meningococcal
disease and 17 (3.9%) of 430 meningococcal
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